ORMP vs PATH
Oramed Pharmaceuticals Inc (ORMP) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Oramed Pharmaceuticals Inc (ORMP) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ORMP revenue for 2023-12-31 was $1.3M. Net income was $5.5M. Revenue was up 48.2% from 2022-12-31 to 2023-12-31. ORMP currently screens at market cap $87.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ORMP currently screens at market cap $87.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ORMP and PATH stock pages for the full models.
Not investment advice.